October 16th 2023
The FDA has approved adjuvant nivolumab to treat completely resected stage IIB/C melanoma.
PER's Breast Cancer Symposia in San Antonio
Register Now!
2023 Friday Satellite Symposia: Preceding the 65th ASH Annual Meeting and Exposition
Register Now!
Updates in Myelodysplastic Syndromes
View More
A Focus on Acute Myeloid Leukemia
View More
The Latest on Acute Lymphocytic Leukemia
View More
Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
8th Annual School of Nursing Oncology™
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Pembrolizumab Potentially Most Effective Before Surgery in High-Risk Melanoma
September 18th 2022The rate of event-free survival associated with pembrolizumab was significantly higher among patients with high-risk melanoma about to undergo surgery than among those who received immunotherapy following surgery.
5-Year Follow-Up Shows Neoadjuvant T-VEC Benefit in Patients with Resectable Melanoma
September 13th 2022The relapse-free survival rate was 22.3% among patients with resectable stage IIIB to IV M1a melanoma who received neoadjuvant talimogene laherparepvec versus 15.2% among those who received surgery alone.
7.5-Year Follow-Up Affirms Nivolumab’s Superiority Over Ipilimumab in Advanced Melanoma
July 13th 2022Nivolumab, whether in combination with ipilimumab or as a monotherapy, was associated with improved overall survival, progression-free survival, and melanoma-specific survival, compared with ipilimumab in advanced melanoma.